• 1
    Cundy TF, O'Grady JG, Williams R. Recovery of menstruation and pregnancy after liver transplantation. Gut 1990; 31:337.
  • 2
    Mass K, Quint EH, Punch MR, Merion RM. Gynecological and reproductive function after liver transplantation. Transplantation 1996; 52:476.
  • 3
    Armenti WT, Radomsky JS, Moritz MJ, Philips LZ, McGrory CH, Coscia LA. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transplantation 2000; 14:121.
  • 4
    Rayes N, Neuhaus N, David M, Steinmüller T, Bechstein WO, Neuhaus P. Pregnancies following liver transplantation–how safe are they? A report of 19 cases under cyclosporine and tacrolimus. Clin Transplantation 1998; 12:396.
  • 5
    Wu A, Nashan B, Messner U, et al. Outcome of 22 successful pregnancies after liver transplantation. Clin Transplantation 1998; 12:454.
  • 6
    Miller JC, Mastrobattista JM, Katz AR. Obstetrical and neonatal outcome in pregnancies after liver transplantation. Am J Perinatol 2000; 17:299.
  • 7
    Armenti VT, Herrine SK, Radomski JS, Moritz MJ. Pregnancy after liver transplantation. Liver Transpl 2000; 6:671.
  • 8
    Carr DB, Larson AM, Schmucker BC, Brateng DA, Carithers RL Jr, Easterling TR. Maternal hemodynamics and pregnancy outcome in women with prior orthotopic liver transplantation. Liver Transpl 2000; 6:213.
  • 9
    Chazouilléres O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP. Occult” hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994; 343:142.
  • 10
    Lowell JO, Howard TK, White HM, et al. Serological evidence of past hepatitis B in liver donor and hepatitis B infection in liver allograft. Lancet 1995; 345:1084.
  • 11
    Perrillo R, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29:1581.
  • 12
    Naoumov NV, Lopes AR, Burra P, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001; 34:888.
  • 13
    Ormonde DG, de Boer WB, Kierath A, et al. Banff schema for grading liver allograft rejection: utility in clinical practice. Liver Transpl Surg 1999; 5:261.
  • 14
    Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103:317.
  • 15
    Roche B, Samuel D, Gigou M, et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997; 26:517.
  • 16
    Uemoto S, Sugiyama K, Marusawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998; 4:494.
  • 17
    Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH. The clinical course of transplantation-associated de novo hepatitis B infections in liver transplant recipients. Liver Transpl Surg 1997; 3:105.
  • 18
    Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HBsAg(-), HbcAb(+), HbcIgM(-) organ donors. Transplantation 1995; 59:230.
  • 19
    Dodson SF, Issa F, Araya V, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997; 64:1582.
  • 20
    Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis B by transplantation of livers from donor positive for antibodies to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113:1668.
  • 21
    Crespo J, Fabrega E, Casafont F, et al. Severe clinical course of hepatitis B infection after liver transplantation. Liver Transpl Surg 1999; 5:175.
  • 22
    Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32:635.
  • 23
    Petry W, Adams O, Haussinger D. Fatal hepatitis B reinfection after orthotopic liver transplantation in an HBsAg negative patient following withdrawal of lamivudine. J Hepatol 2000; 33:514.
  • 24
    Van Nunen AB, de Man RA, Heijtink RA, Niesters HG, Schalm SW. Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients. J Hepatol 2000; 32:1040.
  • 25
    Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999; 36:41.
  • 26
    Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and retroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998; 178:1327.
  • 27
    Bavoux F, Loubeyre-Unique C, Blanche S. Antiretroviral drugs and pregnancy: a proposal of an alert regarding mitochondrial pathology and nucleoside analogs. Arch Pediatr 2000; 7 [Suppl 2]:407s.
  • 28
    Friedman JM, Polifka JE. The effects of drugs on the fetus and nursing infant: a handbook for health care professionals. Baltimore : Johns Hopkins University Press; 1996.
  • 29
    Davison JM. Dialysis, transplantation, and pregnancy. Kidney Dis 1991; 17:127.
  • 30
    Ahlswede KM, Armenti VT, Moritz MJ, et al. Premature births in female renal transplant recipients: degree and effect of immunosuppressive regimen. Surg Forum 1992; 43:524.
  • 31
    Flechner SM, Katz AR, Rogers AJ, et al. The presence of cyclosporine in body tissues and fluids during pregnancy. J Kidney Dis 1985; 5:60.
  • 32
    Nyberg G, Haljamae U, Frisenette, Fich C, Wennergre M, Kjellmer I. Breast-feeding during treatment with cyclosporine. Transplantation 1998; 65:253.
  • 33
    Thiru Y, Bateman DN, Coulthard MG. Successful breast feeding while mother was taking cyclosporin. BMJ 1997; 315:463.